Member Info for WeTookPelham

2 x buys for 17.4p paid, showing on Aquis.

To buy* 1000 shares I should say.

...to 1000 shares.

If only Friggs!

But my estimated guess, and that was all it was, was based on a few things:

- Being here so long!

- Posts from more knoweldgable posters RE MM tactics

Also, it was based on what know:

- Probably the main reason is we have a professional and serious buyer(s) loading up. So we should all be asking why. They don't look done yet, and even of they are, they know something and are waiting, they havent loaded up for nothing.

- The selling looked like PI selling.

- RNS's/trial results imminent, which "seem" to make those big bios drugs look frankly avaerage in comparison (IMO)

- Big bio patent cliffs

But mainly I think things feel different this time, it sounds like Scancell are ready to show the world what they are acheiving and now actually want to get deals done.

Also, so many shots on goal, did someone mention 28?

Someone I'm sure could right a better list, but you get the jist.

RE 400k buyer... Quelle surprise.

Call me crazy but I'm thinking SP might be parity by close or even blue.

Exactly BhuddaBob, making retail panic/knee jerk reactions is the desired outcome here, IMO.

@bobbust - each to their own regarding their own trading stategy, however...I do agree with you also.

The selling today and yesterday looks relatively (esp of late) low volume small PI trades, not large professional trades. Those selling should be asking why has this big time professional buyer(s) been loading up with shares over the last few weeks? They seem very very keen to build a substaintial position. And it is likely they know more than us lowly PI?

Next week could be very interesting IMO.

I'm seeing fractionally more to sell than buy:

18.885 sell price Vs 18.88 buy price.

We saw this earlier this week or last week didn't we?

300k @ 19.40p.

Cheeky little pause to test the weak hands yesterday and this morning?

18.88 to buy/18.71 to sell.

@chippyjo, yes seems so doesn't it. But also a change of tact by trying at the opening bell?

Chilltime putting ivy in his place RE funding, definitely worth a read:

"12/8/2024

07:43 chilltime: Ivy

Do pay attention it has been explained and detailed.

Sclp said cash to early 2025, that was pre fund raise, raise for £6m they said it would take them to mid/late 2025. In the raise they took £6m more which takes the runway into 2026.

The Glymab deal expires Jan 25, if the party proceeds likely $5m up front as per the previous deal.

CFO proactive investor presentation. Glymab existing deal phase 1 2025 which triggers a single digit millions milestone payment.

So the potential to add one or both of those payments to the pot.

The knowledgeable type in this sector suggest phase 2/3 end of 2025.

On top of that there is clearly a strong buyer/fund in the market, who would have approached Scancell first to offer investment (standard game).

The figures, news, and details support cash not needed, hence the buying in the market.

Cash needed post, Scib, Scib+ and all modi combo data.

BMS paid $200m up front for a pre clinical candidate (recently slumped it)

Merck just paid $700m up front, for a phase 1/2 candidate showing efficacy where standard of care had progression. Just like Scancell therapies, showing efficacy where others failed.

BMS in acquisition bolt on mode, Merck the same and both pursuing markets Scancell are in with Scancell therapies providing efficacy upgrades.

Patent cliff situation, is dire, worst ever for them.

Right place right time and can go it alone if needed."

Not sure if this is any help to those on the other forum?

https://www.scancell.co.uk/award-shortlist-a-significant-scientific-endorsement-of-scancells-technology

https://www.proactiveinvestors.co.uk/companies/stocktube/11959/award-shortlist--a-significant-scientific-endorsement--of-scancell-s-technology-11959.html

Should we expect an RNS then if new results?

Same on my broker.

Funny that RW? But yes, must surely just be coincidence.

Also, I wanted to post this on Sunday but got too busy...

"When the last bear turns bull..." etc.

Personally I still struggle to understand this rhetoric, small bio's and/or the pipeline are regularly bought out at much earlier stages than Scancell currently are at. What makes Scancell so different?

Examples: https://www.fiercebiotech.com/biotech/fierce-biotech-ma-tracker-2023

If a potential suitor is waiting in the wings I wouldn't want to give a competitor the opportunity to swoop in instead. IMO.

I can see some bidding war personally.

Typo's/addendum:

"Bolstered*"

"Everything has a price"

Plus the key thing IMO is the patent cliffs.

"I would now prefer a outright purchase, even if for a lot lower than the long term potential of the science."

I'm also in this boat, despite a heavily bolster science and management team that infers standing alone (they have work on this assumption anyway IMO), I feel it's as much a bargaining chip also for a deal.

But also as mentioned by several others, everything thing has a price. Big pharma should find Scancell and it's pipeline very difficult to resist, especially BMS, where it appears to be(?) a great fit.